Clinical Trial Update: Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) [Phase 3]

View source ↗

Summary

Phase 3 trial update on immunogenicity and safety of V419 (PR51) in combination with MCC in infants and toddlers; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections
• Neisseria Meningitidis Disease

Drugs mentioned

• MCC (Meningococcal conjugate vaccine)
• V419 (PR51)

Snippet

Sponsor: MCM Vaccines B.V. | Conditions: Neisseria Meningitidis, Bacterial Infections | Phase 3 | Status: COMPLETED | Results posted: 2019-03-28